Leading stock (600630)
And related reasons: Shanghai Ssangyong High-tech Development Co., Ltd., the holding company of Shanghai SASAC, has a modern textile manufacturing base, and the company holds 94% of the shares, mainly engaged in the development of biological products and new scientific and technological materials.
Main business: brand sales and ethnic trade, clothing and home textiles.
Theme: New Retail Ebola Concept Local State-owned Assets Reform
Company Profile: Shanghai Longtou (Group) Co., Ltd. is mainly engaged in brand sales and international trade. Its main products include knitted underwear, household series, leisure series, underwear, bras, bed sheets, quilt covers, pillowcases, back covers, quilts, blankets, towels, shirts, casual pants, T-shirts, sweaters, jackets, down jackets and coats.
Shuanglu Pharmacy (002038)
And the reason for selection: it has a leading position in the treatment of tumors, liver and kidney diseases, diabetes, cardiovascular and cerebrovascular diseases, and the company is the backbone enterprise of China's genetic engineering drug industry.
Main business: research, development, production and management of genetic engineering and related drugs.
Subject concept: biomedical gene sequencing heparin
Company profile: R&D; P Manage R&D and production, change Jin Duo's military support and the layout of R&D; R&D and its main products include Beijing Shuanglu Pharmaceutical Co., Ltd., which mainly focus on genetic engineering and related drugs, such as recombinant human basic fibroblast growth factor, temozolomide, arsenic trioxide, lenalidomide, compound auxiliary recombinant human granulocyte stimulating factor, recombinant human interleukin-2, recombinant human interleukin-0/1docetaxel and adefovir dipivoxil Xinglin dropping pills. It is related to tumor, liver disease, cardiovascular and cerebrovascular diseases. Enzymes, thymosin, Genhua Fangkaina, Amitabine Dispersible Tablets, the first batch of "100 Innovative Enterprises" in Simixiang Garden, the Beijing Biomedical Industry Leap-forward Development Project (G20 Project), the Zhongguancun National Division being selected as the key high-tech enterprise of the National Torch Program, and the first batch of "100,000 Key Cultivation Enterprises" in Haidian Pharmaceutical Independent Innovation Demonstration Zone of Zhongguancun Science Park.
Qian pharmacy (002550)
And the reason for selection: COVID-19 nucleic acid detection kit of Jinghongsheng Branch, a well-known polysaccharide and protease manufacturer in biochemical pharmaceutical industry in China, has obtained CE certification.
Main business: research and development; D Production and sales of freeze-dried powder, freeze-dried powder injection (including anti-tumor drugs), small-volume injection (not final sterilization), tablets, hard capsules, granules and raw materials within the scope of Drug Production License.
Subject concept: consistency evaluation of common biomedical heparin
Company profile: Changzhou Hongqian Biochemical Pharmaceutical Co., Ltd. is mainly engaged in the research, development, production and sales of freeze-dried powder, freeze-dried powder injection (including anti-tumor drugs), small-volume injection (not final sterilization), tablets, hard capsules, granules and raw materials within the scope of drug production license. The company has 46 product specifications, including tablets, hard capsules, freeze-dried powder and freeze-dried powder injection, small volume injection and raw materials. The main products are biochemical drugs, active enzymes and polysaccharides. Among them, the active enzymes mainly include pancreatic kininogenase series, compound digestive enzyme capsule, elastase, 1- asparaginase series; Polysaccharide varieties mainly include heparin sodium and low molecular weight heparin series varieties. As an expert in the field of animal-derived enzyme preparations, Yi Kai brand, the main variety, was awarded the national well-known trademark.
China Resources Sanjiu (000999)
And the reason for being selected: OTC company ranks first in the overall ranking, with a well-known pharmaceutical brand' 999'. The company's main products include: 999 Ganmaoling, Cephalosporin for Injection, etc.
Main business: research and development; The production and sale of pharmaceutical products and related health services.
Theme concept: state-owned assets reform of central enterprises of influenza traditional Chinese medicine
Company Profile: China Resources Sanjiu Pharmaceutical Co., Ltd. is mainly engaged in research and development, production, sales and related health services of pharmaceutical products. The main products are 999 Ganmaoling, 999 dermatitis flat, Shenfu Injection, Cephalosporin for Injection, Traditional Chinese Medicine Free Decocting, Sanjiu Weitai Granule, Zhengtian Pill, etc. "999" main brand en
And the reason for being selected: it has realized the localization of microbial detection and control technology and become a leading enterprise in the industry. The products such as microbial detection technology series produced by the company are of great value in the field of microbial related drug quality inspection.
Main business: research and development; D manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products and organic analytical instruments.
Theme Concept: Food Safety and Biosafety Testing in COVID-19
Company profile: Zhejiang Tailin Biotechnology Co., Ltd. is mainly engaged in the research and development, manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products and organic analytical instruments. The company's main products are various consumables, instruments and equipment of microbial detection technology series, separation technology series and sterilization technology series. The company was awarded by China Pharmaceutical Equipment Industry Association "the first prize of advanced collective of technological innovation in pharmaceutical equipment industry in China".
Wanfu Biology (300482)
And the reason for selection: excellent supplier of rapid detection products in in vitro diagnosis industry, and the company's colloidal gold new crown antibody detection reagent won the bid for Beijing-Tianjin-Hebei joint collection.
Main business: research and development; Manufacture, sales and service of rapid diagnostic reagents and supporting instruments.
Subject concept: biomedical gene sequencing hepatitis concept
Company Profile: Guangzhou Wanzi Biotechnology Co., Ltd. specializes in the research and development, manufacture, marketing and service of rapid diagnostic reagents and supporting instruments, and is one of the leading POCT enterprises in China. Product lines in major inspection fields such as cardiovascular and cerebrovascular diseases, inflammation, tumors, infectious diseases, drug testing (drug abuse), prenatal and postnatal care. In 20 19, the company obtained the MDSAP certificate for the first time, which proved that the company's quality system met the standards of IS0 13485:20 16 and the regulatory requirements of Australian FDA, HC, TGA and Brazilian ANMISA.
China Resources Crane (600062)
And the reason for selection: the largest infusion supply base in China and the leading production base of fully synthetic antibacterial drugs in China. The company has a long-term production number of Ebola inhibitor drugs and also produces raw materials.
It is more likely to choose the designated point of the State Food and Drug Administration as the indicator of Ebola inhibitors.
Main business: chronic disease business, specialist business, infusion business.
Theme concept: artemisinin influenza heparin state-owned enterprise reform
Company Profile: Huajian Hanfei Pharmaceutical Co., Ltd. is mainly engaged in three major businesses: chronic disease business, specialist business and marketing business. The main products include compound Ping 'an Tea Pai Tablet No.0), Tifurol Sodium Tablet (Zhu), Amlodipine Succinate Tablet (Distar), patented drug Quick Spinning Sustained Release Tablet (Xisu) and Gliclazide Medium Strength Super Tablet (flat storage room) soft bag (including straight soft and sealed polypropylene end infusion).
Nine out of ten people who speculate in stocks don't know "choosing bones, timing and risk control"-this is the root cause of losing money by speculating in bones.
Xiao Lao solemnly promises: Friendship and exchange! Welcome friends with good moral character, high quality and love of learning to discuss with each other!
(1) Learn to look at the market trend and choose a strong sector.
(2) Learn to distinguish between short-term tickets of hot money main force and trend tickets of institutional main force.
(3) Learn to eat meat with the main force and advance and retreat with the main force.
(4) Learn to take profit and stop loss and position management, and bid farewell to heavy losses.
(5) Learn to make trading plans, execute trading plans and sum up experience.
(6) Share the market trend, plate evolution, grasp the logic of cattle and make the most valuable content every day.
Choose the strongest stock, be a top player and encourage you!
Update the exclusive articles and call the auction stock on time at 9: 30 before trading every day, and update the exclusive articles from time to time after closing!
In addition, there was too much bad news over the weekend, and the market sentiment was generally pessimistic. And the more in this case, the more we have to stay awake and calm, and face it frankly. At present, it is not appropriate to continue to say those negative and pessimistic remarks, because it will only increase anxiety and not help.
This week, the most important thing may be to control the position, not to be too rash, and Man Cang should remember to squeeze out some space. During this period, unknown hepatitis suddenly broke out abroad, attacking children, which made people panic. Therefore, the concept of hepatitis has the opportunity to become a speculation point of funds, which can be seen.
Recently, new shares have been broken frequently, which has caused investors' enthusiasm for innovation to drop sharply and their confidence to be seriously frustrated. In order to "the fellow villagers don't go", this week's new shares and sub-new shares may put on a good show and you can watch the performance. There is agriculture, and food is the most important thing for the people, which is expected, and it has just been adjusted so as not to be abandoned.
In fact, it can be seen from some trends over the weekend that the market is actually very tight at present. Of course, the point of tension may be different from ours. However, when the emotions are excessively vented, I believe they can't completely ignore them. After all, the influence is not good.
In a word, be careful to sail for ten thousand years. The most important thing before May Day is defense. After all, if you have a bad week, it will also affect the holiday mood of May Day.
Related Q&A: The leading pharmaceutical unit for treating liver diseases: Fu Rui.
Fu Rui shares (300049): the leader of liver diseases. This company has a medical service platform for the whole industry chain of liver diseases. The main diagnostic product is Fibroscan series liver fibrosis diagnostic instrument, which is the first non-invasive detection equipment for liver fibrosis in the world. Holding 0% equity of French Median13.065438, it is a high-end tumor imaging software provider; /kloc-medical device revenue in 0/7 was 494 million, accounting for 58.09%.
The company's main business is pharmaceutical production and sales, research and development and sales of diagnostic equipment, and medical service business of O2O severe vertical chronic liver disease management.
Features of Fu Rui Company:
The company is a pharmaceutical manufacturer and medical service provider specializing in the field of liver diseases. Its main business is mainly divided into three aspects: pharmaceutical production and sales of compound Biejia Ruangan tablets as the leading products; Production and sale of "Fibroscan" series medical devices for quantitative detection of liver hardness and steatosis; We are establishing a vertically integrated management platform for chronic liver ptosis, providing related medical services and selling related drugs as agents.